RxDoctor Payments Data

Jessica Byrd, MD

Family Medicine · Winchester, VANPI 1639175391

Payments from drug & device makers

$607in general payments, 2019–2025

Across 28 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$204
  • GSK$81
  • Merck$79
  • Abbott$76
  • Pfizer$58
  • Lilly USA, LLC$48
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$607100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk6$204
GSK5$81
Merck4$79
Abbott4$76
Pfizer3$58
Lilly USA, LLC3$48
Medtronic1$29
AstraZeneca1$16
AbbVie1$16

How this compares

$607 in reported general payments places this provider in the 60th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$119,064
Medicare patients
285
Services billed
1,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$95,365
EliquisApixaban44$54,985
JardianceEmpagliflozin42$47,856
TrulicityDulaglutide15$21,180
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$14,109
MounjaroTirzepatide11$11,249
Breo ElliptaFluticasone/Vilanterol15$9,546
SynjardyEmpagliflozin/Metformin Hcl25$8,914
Combivent RespimatIpratropium/Albuterol Sulfate15$7,405
PremarinEstrogens, Conjugated22$5,689
SymbicortBudesonide/Formoterol Fumarate16$4,295
Atorvastatin Calcium474$3,712
Rosuvastatin Calcium338$3,318
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,252
Levothyroxine Sodium309$2,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$204$95,36583 claims
PfizerEliquis, Premarin$58$60,67466 claims
Lilly USA, LLCTrulicity, Mounjaro$48$32,42926 claims
GSKTrelegy Ellipta, Breo Ellipta$81$23,65429 claims
AstraZenecaSymbicort$16$4,29516 claims
AbbVieSynthroid$16$2,39959 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →